Skip to content
OpenCapital
Get started

Acrivon Therapeutics, Inc. ACRV Q4 2024 Annual earnings

Reported March 27, 2025 · Before market open

EPS-$0.60Beat by $0.09
EPS estimate-$0.69

Next report

Aug 12, 2026 (In 2 weeks)
Revenue estimate$386.3K
EPS estimate-$0.49

Versus estimates

Diluted EPS

Q1 2026-$0.49In lineQ4 2025-$0.49In lineQ3 2025-$0.47Beat by $0.10Q2 2025-$0.55Beat by $0.02Q1 2025-$0.51Beat by $0.06
Q4 2024-$0.60Beat by $0.09

Ask the moment Acrivon Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Acrivon Therapeutics, Inc. report Q4 2024 earnings?
Acrivon Therapeutics, Inc. (ACRV) reported Q4 2024 earnings on March 27, 2025 before market open.
What were Acrivon Therapeutics, Inc.'s Q4 2024 revenue and EPS?
Acrivon Therapeutics, Inc. reported eps of $-0.60 for Q4 2024.
Did Acrivon Therapeutics, Inc. beat estimates in Q4 2024?
EPS beat the consensus estimate of $-0.69 by $0.09.
Where can I find Acrivon Therapeutics, Inc.'s Q4 2024 SEC filings?
You can read the 10-K periodic report (0000950170-25-046056) directly on SEC EDGAR. The filing index links above go to sec.gov.